D
Daniel J. Sheward
Researcher at Karolinska Institutet
Publications - 58
Citations - 3539
Daniel J. Sheward is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Antibody & Medicine. The author has an hindex of 17, co-authored 41 publications receiving 2553 citations. Previous affiliations of Daniel J. Sheward include University of Cape Town & Karolinska University Hospital.
Papers
More filters
Journal ArticleDOI
FUBAR : A Fast, Unconstrained Bayesian AppRoximation for inferring selection
Ben Murrell,Sasha Moola,Sasha Moola,Amandla Mabona,Amandla Mabona,Thomas Weighill,Daniel J. Sheward,Sergei L. Kosakovsky Pond,Konrad Scheffler,Konrad Scheffler +9 more
TL;DR: This work presents an approximate hierarchical Bayesian method using a Markov chain Monte Carlo (MCMC) routine that ensures robustness against model misspecification by averaging over a large number of predefined site classes, and leaves the distribution of selection parameters essentially unconstrained.
Journal ArticleDOI
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.
Nicole A. Doria-Rose,Chaim A. Schramm,Jason Gorman,Penny L. Moore,Jinal N. Bhiman,Brandon J. DeKosky,Michael J. Ernandes,Ivelin S. Georgiev,Helen J. Kim,Marie Pancera,Ryan P. Staupe,Han Altae-Tran,Robert T. Bailer,Ema T. Crooks,Albert Cupo,Aliaksandr Druz,Nigel Garrett,Kam Hon Hoi,Rui Kong,Mark K. Louder,Nancy S. Longo,Krisha McKee,Molati Nonyane,Sijy O'Dell,Ryan S. Roark,Rebecca S. Rudicell,Stephen D. Schmidt,Daniel J. Sheward,Cinque Soto,Constantinos Kurt Wibmer,Yongping Yang,Zhenhai Zhang,Nisc Comparative Sequencing,James C. Mullikin,James M. Binley,Rogier W. Sanders,Ian A. Wilson,John P. Moore,Andrew B. Ward,George Georgiou,Carolyn Williamson,Salim S. Abdool Karim,Lynn Morris,Peter D. Kwong,Lawrence Shapiro,John R. Mascola +45 more
TL;DR: HIV-1 V1V2-directed neutralizing antibodies can develop relatively rapidly through initial selection of B cells with a long CDR H3, and limited subsequent somatic hypermutation, and provide important insights relevant to HIV-1 vaccine development.
Journal ArticleDOI
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape
Penny L. Moore,Elin S. Gray,C. Kurt Wibmer,C. Kurt Wibmer,Jinal N. Bhiman,Jinal N. Bhiman,Molati Nonyane,Daniel J. Sheward,Tandile Hermanus,Shringkhala Bajimaya,Nancy Tumba,Melissa-Rose Abrahams,Bronwen E. Lambson,Nthabeleng Ranchobe,Li-Hua Ping,Nobubelo Ngandu,Quarraisha Abdool Karim,Salim S. Abdool Karim,Ronald Swanstrom,Michael S. Seaman,Carolyn Williamson,Lynn Morris,Lynn Morris +22 more
TL;DR: It is shown, in two HIV-1–infected individuals who developed BCN antibodies targeting the glycan at Asn332 on the gp120 envelope, that this glycan was absent on the initial infecting virus, which highlights the dynamic interplay between early antibodies and viral escape in driving the evolution of conserved BCN antibody epitopes.
Journal ArticleDOI
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
Leo Hanke,Laura Vidakovics Perez,Daniel J. Sheward,Daniel J. Sheward,Hrishikesh Das,Tim Schulte,Ainhoa Moliner-Morro,Martin Corcoran,Adnane Achour,Gunilla B. Karlsson Hedestam,B. Martin Hallberg,Ben Murrell,Gerald M. McInerney +12 more
TL;DR: While fusion to an Fc domain renders Ty1 extremely potent, Ty1 neutralizes SARS-CoV-2 spike pseudovirus as a 12.8 kDa nanobody, which can be expressed in high quantities in bacteria, presenting opportunities for manufacturing at scale.
Journal ArticleDOI
Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop
Penny L. Moore,Elin S. Gray,Daniel J. Sheward,Maphuti C. Madiga,Nthabeleng Ranchobe,Zhong Lai,William J. Honnen,Molati Nonyane,Nancy Tumba,Tandile Hermanus,Sengeziwe Sibeko,Koleka Mlisana,Salim S. Abdool Karim,Carolyn Williamson,Abraham Pinter,Lynn Morris +15 more
TL;DR: Comparison of the CAP256 epitope with that of the PG9/PG16 monoclonal antibodies suggested that these epitopes overlapped, adding to the mounting evidence that this may represent a common neutralization target that should be further investigated as a potential vaccine candidate.